Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Hospital length of stay
研究概览
简要总结
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
- •Any prior diet or supplement will be allowed.
- •Age >18 years.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.
研究组 & 干预措施
Nestle Impact Advanced Recovery
Nestle Impact Advanced Recovery
1 dose of Nestle Impact Advanced Recovery orally three times a day
干预措施: Nestle Impact Advanced Recovery (Dietary Supplement)
结局指标
主要结局
Hospital length of stay
时间窗: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge
Days to engraftment
时间窗: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge
次要结局
未报告次要终点
研究者
Greg Monohan
Principal Investigator
University of Kentucky